Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Pasithea Therapeutics Corp. on June 26, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Miami Beach, Florida.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 1,043,248 shares of Common Stock outstanding and entitled to vote, 369,617 shares were represented at the meeting, constituting a quorum. Stockholders acted upon two proposals:
- Proposal 1 (Director Election): Dr. Emer Leahy was elected as a Class I director for a three-year term expiring in 2027.
- Proposal 2 (Auditor Ratification): The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
Voting Breakdown
| Proposal | For | Against/Withheld | Abstain/Non-Votes |
|---|---|---|---|
| Election of Dr. Emer Leahy | 227,198 | 27,223 (Withheld) | 115,196 (Broker Non-Votes) |
| Ratification of Marcum LLP | 333,986 | 34,177 | 1,454 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Dr. Emer Leahy was successfully elected to the Board of Directors.
- Marcum LLP was ratified as the independent auditor for the 2024 fiscal year.
- Approximately 35.4% of outstanding shares were represented at the Annual Meeting.
- Broker non-votes accounted for a significant portion (115,196 shares) of the total outstanding shares regarding the director election.